Exhibit 99.1

FOR IMMEDIATE RELEASE

NU SKIN ENTERPRISES REPORTS FOURTH-QUARTER AND 2018 RESULTS

AND PROVIDES 2019 GUIDANCE

PROVO, Utah — Feb. 13, 2019 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced fourth-quarter and 2018 financial results.

Executive Summary

Q4 2018 vs. Prior-Year Quarter

Revenue:	$683.3 million, +3% ·      (4%) fx impact or ($26.8 M)
Earnings Per Share (EPS):	($0.32), or $1.05 excluding impairment and restructuring charges, compared to $0.33, or $1.20 excluding the impact of U.S. tax reform in Q4 2017 ·      ($1.37) impairment and restructuring charges
Sales Leaders:	73,400; (10%) ·       Up 16% since the end of Q1 2018
Customers:	1,244,000; +16%

2018 Annual

Revenue:	$2.68 billion, +18% ·      0.5% fx impact
Earnings Per Share (EPS):	$2.16, or $3.52 excluding the impairment and restructuring charges, compared to $2.36, or $3.23 excluding the impact of U.S. tax reform

“We delivered another strong quarter despite a challenging comparison from the $130 million LumiSpa introduction in the prior year,” said Ritch Wood, chief executive officer. “We grew our revenue 18 percent for the year, with growth coming from virtually all of our segments. We were also encouraged that our customer acquisition strategy resulted in 16-percent growth in our customer base. And while our sales leader numbers were down year-over-year due to the LumiSpa introduction, we are pleased with 16 percent growth in sales leaders since the first quarter.”

Q4 2018 Year-Over-Year Operating Results

Revenue:	$683.3 million compared to $666.2 million ·      (4%) fx impact or ($26.8 M)
Gross Margin:	76.3% compared to 77.7% Nu Skin business was 77.9%
Selling Expenses:	39.4% of revenue compared to 39.8% ·      Nu Skin business was 40.9%
G&A Expenses:	23.9% of revenue compared to 23.0%
Operating Margin:	2.7% or 14.1% when excluding impairment and restructuring charges, compared to 14.9%
Other Income / (Expense):	($4.3) million expense compared to ($0.4) million expense
Income Tax Rate:	225% or 35.9% excluding impairment and restructuring charges, compared to 81.5% or 33.1% excluding the impact of U.S. tax reform
EPS:	($0.32), or $1.05 excluding impairment and restructuring charges, compared to $0.33, or $1.20 excluding the impact of U.S. tax reform ·       ($1.37) impairment and restructuring charges

Stockholder Value

Dividend Payments:	$20.2 million
Stock Repurchases:	$21.3 million; $471 million remaining in authorization

Q1 and Full-Year 2019 Outlook

Q1 2019 Revenue:	$615 to $635 million, 0 to 3% growth ·      6 to 8% constant currency growth ·      Approximately (5 to 6%) fx impact
Q1 2019 EPS:	$0.70 to $0.77
2019 Revenue:	$2.76 billion to $2.82 billion,  3 to 5% growth ·      5 to 7% constant currency growth ·      Approximately (2 to 3%) fx impact
2019 EPS	$3.80 to $4.05

“We are entering 2019 with strong momentum and are projecting meaningful constant-currency top-line growth with continued improvement on the bottom line,” said Wood. “We believe 2019 will be a pivotal year as we transform our digital platform to better support customers, while further enabling our sales leaders to leverage the power of social selling. Our product portfolio remains strong, and we plan to build on the breakout success of our LumiSpa skin treatment and cleansing device with the launch of LumiSpa Accent, a specialized eye treatment attachment. On the program front, our Velocity enhanced sales compensation program has now been rolled out in nearly every market, providing us with ongoing flexibility to drive and reward key behaviors from our sales force. We believe we can continue to grow our business and look forward to a strong 2019,” Wood concluded.

“Coming off a strong year, we are projecting continued growth in 2019,” said Mark Lawrence, chief financial officer. “We project first-quarter revenue of $615 to $635 million, including an approximate 5 to 6 percent negative currency impact, and earnings per share of $0.70 to $0.77. For the year, we are projecting annual revenue of $2.76 to $2.82 billion with a projected 2 to 3 percent negative foreign currency impact and earnings per share of $3.80 to $4.05. We look forward to providing additional details regarding our guidance and 2019 growth initiatives at our investor day event which will be held Feb. 28 at our headquarters,” concluded Lawrence.

Conference Call

The Nu Skin management team will host a conference call with the investment community on Feb. 13, 2019, at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available at the same URL through Feb. 27, 2019.

About Nu Skin Enterprises, Inc.

Founded more than 30 years ago, Nu Skin Enterprises, Inc. develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin^® personal care brand, the Pharmanex^® nutrition brand, and most recently, the ageLOC^® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC LumiSpa skin cleansing and treatment device, ageLOC Youth nutritional supplement, the ageLOC Me^® customized skin care system, as well as the ageLOC TR90^® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry’s consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin is also traded on the New York Stock Exchange under the symbol “NUS.” More information is available at nuskin.com.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, product launches, strategies and initiatives; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “project,” “anticipate,” “estimate,” “intend,” “plan,” “continue,” “targets,” “likely,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

· adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

· risk that direct selling laws and regulations in any of our markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;

· any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

· risk of foreign currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

· uncertainties regarding the future financial performance of the company’s recent acquisitions;

· risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

· regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit the company’s ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;

· unpredictable economic conditions and events globally;

· uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and

· continued competitive pressures in the company’s markets.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue growth is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period’s revenue. Operating margin, income tax rate and earnings per share, each excluding impairment and restructuring charges and/or the impact of tax reform, also are non-GAAP financial measures. Impairment and restructuring charges are not part of the ongoing operations of our underlying business. The U.S. tax reform legislation was enacted in December 2017 and had a material impact on our tax rate and earnings per share. Removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our operating margin, income tax rate and earnings per share calculated under GAAP, below.

The Company’s revenue results by segment for the three-month periods ended December 31 are presented in the following table (in thousands).

	2018		2017		% Change			Constant Currency % Change
Mainland China	$	217,040	$	222,333		(2	%)		2	%
Americas/Pacific		95,175		102,335		(7	%)		3	%
South Korea		102,840		103,066		—			2	%
Southeast Asia		80,500		73,920		9	%		13	%
Japan		63,953		67,620		(5	%)		(6	%)
Hong Kong/Taiwan		47,746		46,627		2	%		4	%
EMEA		50,584		47,890		6	%		10	%
Other		25,449		2,410		956	%		956	%
Total	$	683,287	$	666,201		3	%		7	%

The Company’s revenue results by segment for the year ended December 31 are presented in the following table (in thousands).

	2018		2017		% Change			Constant Currency % Change
Mainland China	$	886,472	$	716,991		24	%		21	%
Americas/Pacific		385,034		342,429		12	%		20	%
South Korea		373,357		361,692		3	%		1	%
Southeast Asia		316,890		268,631		18	%		18	%
Japan		254,939		256,085		—			(2	%)
Hong Kong/Taiwan		185,893		166,696		12	%		11	%
EMEA		182,394		160,275		14	%		10	%
Other		94,029		6,300		1,393	%		1,393	%
Total	$	2,679,008	$	2,279,099		18	%		17	%

The company’s Customers and Sales Leaders statistics by segment for the three-month periods ended December 31 are presented in the following table.

	2018				2017				% Increase (Decrease)
	Customers		Sales Leaders		Customers		Sales Leaders		Customers			Sales Leaders
Mainland China		304,000		33,100		193,000		40,600		58	%		(18	%)
Americas/Pacific		249,000		8,300		244,000		8,900		2	%		(7	%)
South Korea		182,000		7,600		173,000		8,400		5	%		(10	%)
Southeast Asia		153,000		8,900		122,000		8,000		25	%		11	%
Japan		130,000		5,900		132,000		6,600		(2	%)		(11	%)
Hong Kong/Taiwan		77,000		4,800		71,000		4,700		8	%		2	%
EMEA		149,000		4,800		135,000		4,700		10	%		2	%
Total		1,244,000		73,400		1,070,000		81,900		16	%		(10	%)

“Customers” are persons who purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.

“Sales Leaders” are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(in thousands, except per share amounts)

	Three Months Ended December 31,						Years Ended December 31,
	2018			2017			2018			2017
Revenue	$	683,287		$	666,201		$	2,679,008		$	2,279,099
Cost of sales		161,853			148,459			634,140			502,078
Gross profit		521,434			517,742			2,044,868			1,777,021
Operating expenses:
Selling expenses		269,052			265,378			1,071,020			938,024
General and administrative expenses		163,265			153,244			662,302			564,514
Restructuring and impairment expenses		70,686			—			70,686			—
Total operating expenses		503,003			418,622			1,804,008			1,502,538
Operating income		18,431			99,120			240,860			274,483
Other income (expense), net		(4,254	)		(446	)		(21,194	)		(8,916	)
Income before provision for income taxes		14,177			98,674			219,666			265,567
Provision for income taxes		31,936			80,439			97,779			136,130
Net income	$	(17,759	)	$	18,235		$	121,887		$	129,437
Net income per share:
Basic	$	(0.32	)	$	0.35		$	2.21		$	2.45
Diluted	$	(0.32	)	$	0.33		$	2.16		$	2.36
Weighted-average common shares outstanding (000s):
Basic		55,453			52,722			55,170			52,806
Diluted		56,341			55,053			56,476			54,852

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(in thousands)

	December 31, 2018			December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	386,911		$	426,399
Current investments		11,346			11,847
Accounts receivable		53,282			33,196
Inventories, net		295,821			253,454
Prepaid expenses and other		51,877			52,893
		799,237			777,789
Property and equipment, net		464,535			464,587
Goodwill		196,573			114,954
Other intangible assets, net		89,989			67,647
Other assets		144,112			164,895
Total assets	$	1,694,446		$	1,589,872
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	47,617		$	50,341
Accrued expenses		322,583			319,189
Current portion of long-term debt		69,455			77,840
		439,655			447,370
Long-term debt		361,008			310,790
Other liabilities		111,916			127,116
Total liabilities		912,579			885,276
Stockholders’ equity:
Class A common stock		91			91
Additional paid-in capital		552,564			466,349
Treasury stock, at cost		(1,326,605	)		(1,304,694	)
Accumulated other comprehensive loss		(79,934	)		(66,318	)
Retained earnings		1,635,751			1,609,168
		781,867			704,596
Total liabilities and stockholders’ equity	$	1,694,446		$	1,589,872

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Tax

Reform to GAAP Earnings Per Share

(in thousands, except per share amounts)

	Three Months Ended December 31,					Years Ended December 31,
	2018			2017		2018			2017
Net income	$	(17,759	)	$	18,235	$	121,887		$	129,437
Impact of restructuring and impairment:
Restructuring and impairment		70,686			—		70,686			—
Inventory write-off		7,240			—		7,240			—
Income tax impact		(1,086	)		—		(1,086	)		—
Impact of tax reform on provision for income taxes		—			47,729		—			47,729
Adjusted net income	$	59,081		$	65,964	$	198,727		$	177,166
Diluted earnings per share	$	(0.32	)	$	0.33	$	2.16		$	2.36
Diluted earning per share, excluding restructuring and tax reform impact	$	1.05		$	1.20	$	3.52		$	3.23
Weighted-average common shares outstanding (000s):		56,341			55,053		56,476			54,852

NU SKIN ENTERPRISES, INC.

Reconciliation of Operating Margin Excluding Impact of Restructuring to GAAP

Operating Margin

(in thousands, except per share amounts)

	Three Months Ended December 31,						Years Ended December 31,
	2018			2017			2018			2017
Operating income	$	18,431		$	99,120		$	240,860		$	274,483
Impact of restructuring and impairment:
Restructuring and impairment		70,686			—			70,686			—
Inventory write-off		7,240			—			7,240			—
Adjusted operating income	$	96,357		$	99,120		$	318,786		$	274,483
Operating margin		2.7	%		14.9	%		9.0	%		12.0	%
Operating margin, excluding restructuring impact		14.1	%		14.9	%		11.9	%		12.0	%
Revenue	$	683,287		$	666,201		$	2,679,008		$	2,279,099

NU SKIN ENTERPRISES, INC.

Reconciliation of Effective Tax Rate Excluding Impact of Restructuring and Tax

Reform to GAAP Effective Tax Rate

(in thousands, except per share amounts)

	Three Months Ended December 31,						Years Ended December 31,
	2018			2017			2018			2017
Provision for income taxes	$	31,936		$	80,439		$	97,779		$	136,130
Impact of restructuring on tax provision		1,086			—			1,086			—
Impact of tax reform on provision for income taxes		—			(47,729	)		—			(47,729	)
Provision for income taxes, excluding impact of restructuring and tax reform	$	33,022		$	32,710		$	98,865		$	88,401
Income before provision for income taxes	$	14,177		$	98,674		$	219,666		$	265,567
Impact of restructuring and impairment:
Restructuring and impairment		70,686			—			70,686			—
Inventory write-off		7,240			—			7,240			—
Income before provision for income taxes, excluding impact of restructuring and tax reform	$	92,103		$	98,674		$	297,592		$	265,567
Effective tax rate		225.3	%		81.5	%		44.5	%		51.3	%
Effective tax rate, excluding restructuring and tax reform impact		35.9	%		33.1	%		33.2	%		33.3	%

# # #

Nu Skin Social Media Channels

 fb.com/nuskin   twitter.com/nuskin  instagram.com/nuskin

CONTACTS:Media: media@nuskin.com, (801) 345-6397

Investors: investorrelations@nuskin.com,  (801) 345-3577